Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

NCT01926028 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

188

Enrollment

INDUSTRY

Sponsor class

Conditions

Vulvovaginal Candidiasis

Interventions

BIOLOGICAL: NDV-3A
BIOLOGICAL: NDV-3
BIOLOGICAL: Placebo

Sponsor

NovaDigm Therapeutics, Inc.